F D C Ltd

FDC Limited (NSE: FDC, BSE: 531599) announced its unaudited financial results for the first quarter ended June 30, 2026, reporting consolidated revenue from operations of Rs. 668 crore, a 3.0% year-over-year increase compared to Rs. 648 crore in the same quarter of the previous year, driven primarily by the performance of International Formulations, particularly the US business, while Domestic Formulations and APIs remained relatively muted. The company also received U.S. FDA approval for Cefixime for Oral Suspension USP 100mg/5mL and 200mg/5mL during the quarter.

FDC Ltd share price remained flat to Rs 403.0. The Company's net profit soared by 28.13% to Rs 132.49 crore, while revenue from operations gained 14.18% to Rs 667.69 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, rising 5.74%. It has marginally improved by 0.41% over last one week and advanced by 11.45% in last one month while the market capitalization of FDC Ltd has eased by 2.73% and 7.34% in the same period respectively. Profit before tax (PBT) of FDC Ltd stood at Rs 174.7 crore in Q2 FY26, easing 9.34% year-on-year, and jumping 24.47% quarter-on-quarter. EBITDA came in at Rs 95 crore, slipping 9.08% YoY and surging by 68.80% sequentially. Total expenses grew marginally by 9.55% to Rs 539.82 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 144.5 crore, marginally falling by 2.97% YoY, while employee benefits expense was at Rs 135.16 crore, surging 23.66% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 8.50% to Rs 2108.12 crore, while net profit dropped 12.55% to Rs 266.79 crore, compared to previous TTM. EBITDA surged by 24972% to Rs 234.14 crore, and PBT saw a marginal contraction of 9.84% to Rs 357.22 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 317.57 crore in FY26, as against Rs 220.77 crore in FY25. FDC Ltd nosedived by 16.33% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.20% during the same period.

FDC will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Net profit of FDC rose 167.39% to Rs 103.40 crore in the quarter ended March 2026 as against Rs 38.67 crore during the previous quarter ended March 2025. Sales rose 18.89% to Rs 584.79 crore in the quarter ended March 2026 as against Rs 491.89 crore during the previous quarter ended March 2025. For the full year,net profit rose 5.48% to Rs 281.42 crore in the year ended March 2026 as against Rs 266.79 crore during the previous year ended March 2025. Sales rose 2.98% to Rs 2170.93 crore in the year ended March 2026 as against Rs 2108.12 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales584.79491.89 19 2170.932108.12 3 OPM %18.1910.97 -15.9415.41 - PBDT154.7068.87 125 454.63410.95 11 PBT140.3553.31 163 395.39357.22 11 NP103.4038.67 167 281.42266.79 5 Powered by Capital Market - Live

Net profit of FDC rose 122.04% to Rs 107.07 crore in the quarter ended March 2026 as against Rs 48.22 crore during the previous quarter ended March 2025. Sales rose 17.09% to Rs 564.36 crore in the quarter ended March 2026 as against Rs 482.00 crore during the previous quarter ended March 2025. For the full year,net profit rose 4.49% to Rs 285.92 crore in the year ended March 2026 as against Rs 273.63 crore during the previous year ended March 2025. Sales rose 2.72% to Rs 2126.33 crore in the year ended March 2026 as against Rs 2070.11 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales564.36482.00 17 2126.332070.11 3 OPM %19.7810.96 -16.5615.47 - PBDT157.2783.08 89 458.25421.29 9 PBT142.9667.55 112 399.15367.68 9 NP107.0748.22 122 285.92273.63 4 Powered by Capital Market - Live

FDC will hold a meeting of the Board of Directors of the Company on 27 May 2026.

FDC has granted ANDA approval by United States Food and Drug Administration (U.S.FDA), for Cefixime for Oral Suspension USP, 100 mg / 5 mL and 200 mg/ 5 mL.

Net profit of FDC declined 23.60% to Rs 28.30 crore in the quarter ended December 2025 as against Rs 37.04 crore during the previous quarter ended December 2024. Sales rose 0.13% to Rs 464.71 crore in the quarter ended December 2025 as against Rs 464.11 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales464.71464.11 0 OPM %11.2510.05 - PBDT71.9664.53 12 PBT57.1751.18 12 NP28.3037.04 -24 Powered by Capital Market - Live

FDC announced that the Board of Directors of the Company at its meeting held on 05 February 2026, has recommended a First Interim Dividend of Rs.5 per share (i.e.500%), subject to the approval of the shareholders.Powered by Capital Market - Live

FDC will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live